Document is current
Any future updates will be listed below
-
Authors
Patrick, McKenzie
Gu, Zhimin
Zhang, Gen
Wynn, R. Max https://orcid.org/0000-0002-1879-2136
Kaphle, Pranita
Cao, Hui
Vu, Hieu
Cai, Feng
Gao, Xiaofei
Zhang, Yuannyu
Chen, Mingyi https://orcid.org/0000-0001-6754-0480
Ni, Min
Chuang, David T.
DeBerardinis, Ralph J. https://orcid.org/0000-0002-2705-7432
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (PR191670)
U.S. Department of Health & Human Services | National Institutes of Health (R35CA22044901)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA230631)
U.S. Department of Health & Human Services | National Institutes of Health (R01CA259581)
U.S. Department of Health & Human Services | National Institutes of Health (R01DK111430)
U.S. Department of Health & Human Services | National Institutes of Health (R21AI158240)
Cancer Prevention and Research Institute of Texas (RP180778)
Cancer Prevention and Research Institute of Texas (RP180504)
Cancer Prevention and Research Institute of Texas (RP190417)
Cancer Prevention and Research Institute of Texas (RP220337)
Cancer Prevention and Research Institute of Texas (RP220375)
- License Information
-
More Information
Article History
Received: 28 February 2022
Accepted: 14 October 2022
First Online: 28 November 2022
Competing interests
: M.P. and J.X. have a pending patent application for the use of BCAT isozymes to treat metabolic disorders. M.P., J.X., and The University of Texas Southwestern Medical Center have a financial interest in the pending patent application.
